🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchOrforglipron ATTAIN-4 — my results so far Page 4

Orforglipron ATTAIN-4 — my results so far

roxy_nash Sat, Jul 12, 2025 at 6:46 AM 43 replies 2,076 viewsPage 4 of 9
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Jul 25, 2025 at 10:57 AM#16

Adding the clinical framing, because it changes how the question reads. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

Last edited: Jul 25, 2025 at 2:57 PM
14 12steve_okc, dave_SLC, FDA_TrackerJim and 11 others
Reply Quote Save Share Report
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Jul 27, 2025 at 1:49 PM#17
josh_phd_bmore said:
If you are going to change something, change one thing and give it long enough to express itself.

Bookmarking. The distinction being drawn above is the one nobody else makes.

Last edited: Jul 27, 2025 at 4:49 PM
15 13VanRx_Mike, steve_okc, dave_SLC and 12 others
Reply Quote Save Share Report
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
Jul 29, 2025 at 4:42 PM#18

From the other side of the consultation, briefly. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Jul 29, 2025 at 7:42 PM
16 14amsterdam_pete, LondonLisa, mike_nyc and 13 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Jul 31, 2025 at 7:36 PM#19
LindaRN_retired said:
Worth answering the question that was asked rather than the one behind it.

Second this. I had assumed I was the exception until I read this.

17 15DebRD_ATL, KristenIndy, MarkLI_maint and 14 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Aug 2, 2025 at 10:31 PM#20

Moderator note: the sourcing question belongs in the vendor section and has been split out.

39 12PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 36 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register